


Tenofovir-Based PrEP for African Women
VOICE

Tenofovir-Based PrEP for African Women


VOICE Trial: Study Design

- **Background:** Randomized, placebo-controlled trial to assess daily treatment with oral tenofovir disoproxil fumarate (TDF), oral tenofovir-emtricitabine (TDF-FTC), or 1% tenofovir (TFV) vaginal gel as HIV PrEP in women in South Africa, Uganda, and Zimbabwe
- **Participants** (n = 5029) women
 - Age 18-45 years
 - Cisgender women
 - Reported vaginal sex in previous 3 months
 - Not pregnant or breastfeeding
 - Willing to use effective contraception
- **Regimens**
 - Tenofovir mg PO daily (TDF tablet)
 - Tenofovir-emtricitabine PO daily (TDF-FTC) tablet
 - Tenofovir 1% gel daily (TFV gel)




Tenofovir-Based PrEP for African Women

VOICE Trial: Background




Abbreviations: TDF = tenofovir; TDF-FTC = tenofovir DF-emtricitabine

Vaginal and Oral Interventions to Control the Epidemic VOICE Trial: Timeline




Vaginal and Oral Interventions to Control the Epidemic VOICE Trial: Results



*Data censored at time that oral TDF arm stopped

Vaginal and Oral Interventions to Control the Epidemic VOICE Trial: Adherence

Mean Proportion of Quarterly Samples with Tenofovir Detected (%)



Vaginal and Oral Interventions to Control the Epidemic VOICE Trial: Conclusions

Conclusions: “None of the drug regimens we evaluated reduced the rates of HIV-1 acquisition in an intention-to-treat analysis. Adherence to study drugs was low.”

Acknowledgments

The **National HIV Curriculum** is supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of a financial assistance award totaling \$1,021,448 with 0% financed with non-governmental sources. The contents are those of the author(s) and do not necessarily represent the official views of, nor an endorsement, by HRSA, HHS, or the U.S. Government. For more information, please visit HRSA.gov. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.

